Definium Therapeutics, Inc.
Financials
Valuation Metrics
Definium Therapeutics, Inc.'s Market Cap is $5.21B. At end of 2025 it was $1.20B. Ranked #1328 of 3,121 in US market (top 43%), #450 of 1,463 on NASDAQ (top 31%), #80 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.21B | US#1,328/3,121 Sec#80/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-354M | US—/3,121 Sec—/266 |
| Total Assets | $1.11B | US#2,426/3,121 Sec#95/266 |
| Net Assets | $919M | US#1,820/3,121 Sec#71/266 |
| Employees | 106 | US#2,615/3,121 Sec#174/266 |
| Value | ||
| P/B | 5.68x | US#2,315/3,121 Sec#152/266 |
| FCF Yield | -3.20% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -38.51% | US#2,619/3,121 Sec#132/266 |
| ROA | -31.79% | US#2,896/3,121 Sec#161/266 |
| Financial Health | ||
| Debt Ratio | 21.14% | US#241/3,121 Sec#81/266 |
| Total Debt | $36M | US#2,667/3,121 Sec#169/266 |
| FCF | $-167M | US#2,744/3,121 Sec#192/266 |
| Cash | $655M | US#901/3,121 Sec#43/266 |
| Current Ratio | 6.95x | US#360/3,121 Sec#113/266 |
| Performance | ||
| 1Y Return | 309.39% | US#28/3,121 Sec#13/266 |
| 1M Return | -15.30% | US#2,867/3,121 Sec#228/266 |
| From 52W High | -21.91% | US#1,632/3,121 Sec#122/266 |
| 1Y MDD | -24.79% | US#1,047/3,121 Sec#51/266 |
| Trading | ||
| Volume | 1,526,079 shares | US#952/3,121 Sec#97/266 |
| Trading Value | $59M | US#1,080/3,121 Sec#82/266 |
| Per Share | ||
| EPS | $-2.63 | US—/3,121 Sec—/266 |
| BPS | $6.84 | US#2,110/3,121 Sec#102/266 |
Company Info
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.